127 results
Page 3 of 7
8-K
EX-99.1
1jfk1gojv 9hvz
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
ay1mw3p4stg s0yfg8
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-99.1
awab3z cur0
6 May 21
Adaptimmune Reports First Quarter Financial Results and Business Update
7:38am
8-K
EX-99.1
4cmgei f0f2h
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
xc2q2y lypvsn70
20 Nov 20
Regulation FD Disclosure
7:36am
S-3ASR
29eohmew3 sxaee
10 Aug 20
Automatic shelf registration
5:01pm
424B5
b9u9c457ty
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
ixls0j3e
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
vy8 dogy2n8
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
EX-99.1
7usnl0dx7cw4k5m
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am